Back to News
Market Impact: 0.42
BioMarin Reports Positive Phase 3 Results For VOXZOGO
Source: Nasdaq
Healthcare & BiotechProduct Launches
BioMarin reported positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia. The trial met its primary endpoint and all secondary efficacy endpoints, strengthening the clinical case for a potential expansion of VOXZOGO's addressable patient population.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
BMRN0.88
More News
- BioMarin at Wells Fargo conference: growth, pipeline and integration
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test